- Home
- ONFO vs GRI Comparison
ONFO vs GRI Comparison
Compare ONFO & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- GRI
- Stock Information
- Founded
- ONFO 2018
- GRI 2018
- Country
- ONFO United States
- GRI United States
- Employees
- ONFO N/A
- GRI N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- ONFO Technology
- GRI Health Care
- Exchange
- ONFO Nasdaq
- GRI Nasdaq
- Market Cap
- ONFO 6.7M
- GRI 6.1M
- IPO Year
- ONFO 2022
- GRI N/A
- Fundamental
- Price
- ONFO $1.26
- GRI $0.72
- Analyst Decision
- ONFO
- GRI Strong Buy
- Analyst Count
- ONFO 0
- GRI 2
- Target Price
- ONFO N/A
- GRI $11.50
- AVG Volume (30 Days)
- ONFO 158.2K
- GRI 182.9K
- Earning Date
- ONFO 11-15-2024
- GRI 11-14-2024
- Dividend Yield
- ONFO N/A
- GRI N/A
- EPS Growth
- ONFO N/A
- GRI N/A
- EPS
- ONFO N/A
- GRI N/A
- Revenue
- ONFO $6,590,171.00
- GRI N/A
- Revenue This Year
- ONFO $133.59
- GRI N/A
- Revenue Next Year
- ONFO N/A
- GRI N/A
- P/E Ratio
- ONFO N/A
- GRI N/A
- Revenue Growth
- ONFO 29.25
- GRI N/A
- 52 Week Low
- ONFO $0.39
- GRI $0.30
- 52 Week High
- ONFO $1.88
- GRI $65.00
- Technical
- Relative Strength Index (RSI)
- ONFO 44.75
- GRI 44.58
- Support Level
- ONFO $1.15
- GRI $0.68
- Resistance Level
- ONFO $1.39
- GRI $0.77
- Average True Range (ATR)
- ONFO 0.09
- GRI 0.07
- MACD
- ONFO -0.01
- GRI -0.01
- Stochastic Oscillator
- ONFO 36.67
- GRI 16.44
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.